Gulbrandsen Technologies is proud to announce its participation in the DCVMN Annual General Meeting 2025. This prestigious global gathering brings together vaccine manufacturers, researchers, and innovators dedicated to improving global immunization access and quality.
You can meet our team at Booth B7, where we will be showcasing our vaccine adjuvants developed under our Life Sciences division. Our products are designed with uncompromising standards of quality, safety, and consistency to support the development of effective and stable vaccines. HydroVAC features aluminum oxyhydroxide-based adjuvants ideal for neutral or negative antigens, while PhosVAC offers aluminum phosphate-based adjuvants optimized for positive or neutral antigens.
We will also share updates on new adjuvants in our pipeline, including innovative emulsions, immunomodulators and complex systems being designed to meet the evolving needs of vaccine manufacturers worldwide. With a focus on scientific innovation, global reach, and customer collaboration, Gulbrandsen Technologies is committed to advancing vaccine adjuvants and its formulation technologies that contribute to a safer, healthier world.
Representing Gulbrandsen Technologies at DCVMN 2025 will be new business development team to seek collaboration and partnerships with focus on innovation.
📍 Booth: B7
📅 Date: October 29th – 31st, 2025
📌 Location: Bali, Indonesia
📝 Event: DCVMN Annual General Meeting 2025
📧 Contact: lifesciences@gulbrandsen.com
Join us at DCVMN 2025 and discover how we can collaborate to enhance global vaccine development.